Access to POEMs and Essential Evidence Plus will no longer be included in CMA membership as of Dec. 1, 2023.
Clinical Question
Does increased vegetable intake reduce the risk of cancer progression in men with early-stage prostate cancer?
Bottom line
The Men's Eating and Living (MEAL) Study found that increasing vegetable intake did not prevent disease progression in men with early-stage prostate cancer managed with active surveillance. 1b
Reference
Study design: Randomized controlled trial (single-blinded)
Funding: Government
Setting: Outpatient (specialty)
Synopsis
Current recommendations widely circulated in the public domain encourage the consumption of diets high in vegetables to reduce the risk of disease progression in patients with early-stage prostate cancer. These investigators identified men, aged 50 to 80 years, with early-stage prostate cancer based on standard international diagnostic criteria and managed with active surveillance. Eligible patients (N = 443) randomly received assignment (concealed allocation) to either a telephone-based counseling intervention or a usual-care control group. Intervention participants were assigned to a counselor who encouraged the consumption of a diet high in leafy green, carotenoid, and cruciferous vegetables through 16 regularly scheduled counseling telephone calls over a 2-year period. Control participants received printed materials encouraging consumption of a vegetable-rich diet. Prostate-specific antigen (PSA) testing occurred every 3 months, starting at baseline, and participants who did not meet the criteria for additional cancer treatment underwent an end-of-study biopsy at 24 months. The study was at least 80% powered to detect a predetermined clinically meaningful 10% group difference in cancer progression rates. Intervention participants reported a significant increase in daily total vegetable servings compared with controls. Plasma carotenoids measured at 12 months in a random of sample of participants validated self-reported dietary data. Using both per-protocol and intention-to-treat analyses, no significant group differences occurred in the primary outcome of PSA level of 10 ng/mL or greater, PSA doubling time of less than 3 years, or upgrading of either tumor volume or grade on follow-up prostate biopsy.
Reviewer
David C. Slawson, MD
Professor and Vice Chair of Family Medicine for Education and Scholarship
Atrium Health
Professor of Family Medicine, UNC Chapel Hill
Charlotte, NC